Kinenza (enzastaurin)

News alerts, weekly reports and conference planners

Company:

Aytu BioPharma, Denovo

Drug class:

PI3K inhibitor, AKT inhibitor, PKCβ inhibitor

No biomarker	Glioblastoma	No biomarker	Glioblastoma	enzastaurin Sensitive: B - Late Trials enzastaurin Sensitive : B	enzastaurin Sensitive: B - Late Trials enzastaurin Sensitive : B
GNAQ Q209P	Uveal Melanoma	GNAQ Q209P	Uveal Melanoma	enzastaurin Sensitive: D – Preclinical enzastaurin Sensitive : D	enzastaurin Sensitive: D – Preclinical enzastaurin Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	enzastaurin Sensitive: D – Preclinical enzastaurin Sensitive : D	enzastaurin Sensitive: D – Preclinical enzastaurin Sensitive : D

Associations
(3)